Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease
Status:
RECRUITING
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat. Eligible patients are randomly assigned 1:1 to the high-hemoglobin target group hemoglobin of 13 g/dland low-hemoglobin target group hemoglobin of 11 g/dland administered with enarodustat to achieve and maintain target hemoglobin over 96 weeks. The first primary endpoint was the difference of mean change in 36-Item Short Form Health Survey at week 24. The second primary endpoint was safety endpoints included time to major adverse cardiovascular + event (MACE+; all-cause mortality, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) during 96 weeks.